Citations

Mayo Clinic

Showing 10 of 108599 citations.

Implementation of an interprofessional clinical pharmacology selective learning experience for pharmacy residents and medical students
Schramm, Garrett E. , Narayanan, Prasanna P., Chutka, Darryl S., Nicholson, Wayne T.

American Journal of Health-System Pharmacy | March 8, 2017 | Volume: 74 | Issue: 6 | Pages: 397-401

10.2146/ajhp160112 | PMID 28274982 Get It

Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy
Higgins, Erin M. , Bos, J. Martijn , Mason‐Suares, Heather , Tester, David J. , Ackerman, Jaeger P., MacRae, Calum A. , Sol‐Church, Katia, Gripp, Karen W. , Ackerman, Michael J. , Urrutia, Raúl , Bos, Johan M

JCI Insight | March 8, 2017 | Volume: 2 | Issue: 5 | Pages: No page available

10.1172/jci.insight.91225 | PMID 28289718 Get It

Noonan syndrome (NS; MIM 163950) is an autosomal dominant disorder and a member of a family of developmental disorders termed “RASopathies,” which are caused mainly by gain-of-function mutations in genes encoding RAS/MAPK signaling pathway proteins. Whole exome sequencing (WES) and trio-based genomic triangulation of a 15-year-old female with a clinical diagnosis of NS and concomitant cardiac hypertrophy and her unaffected parents identified a de novo variant in MRAS -encoded RAS-related protein 3 as the cause of her disease. Mutation analysis using in silico mutation prediction tools and molecular dynamics simulations predicted the identified variant, p.Gly23Val-MRAS, to be damaging to normal protein function and adversely affect effector interaction regions and the GTP-binding site. Subsequent ectopic expression experiments revealed a 40-fold increase in MRAS activation for p.Gly23Val-MRAS compared with WT-MRAS. Additional biochemical assays demonstrated enhanced activation of both RAS/MAPK pathway signaling and downstream gene expression in cells expressing p.Gly23Val-MRAS. Mutational analysis of MRAS in a cohort of 109 unrelated patients with phenotype-positive/genotype-negative NS and cardiac hypertrophy yielded another patient with a sporadic de novo MRAS variant (p.Thr68Ile, c.203C>T). Herein, we describe the discovery of mutations in MRAS in patients with NS and cardiac hypertrophy, establishing MRAS as the newest NS with cardiac hypertrophy-susceptibility gene.
Endoscopic anterior–posterior cricoid split for pediatric bilateral vocal fold paralysis
Rutter, Michael J. , Alarcón, Alessandro de , Parikh, Sanjay R., Balakrishnan, Karthik , Lam, Derek J. , Johnson, Kaalan , Sidell, Douglas R. , Sidell, Douglas R. , Hart, Catherine K. , Daniel, Sam Joseph , Sidell, Douglas R , Lam, Derek J , Balakrishnan, Karthik

The Laryngoscope | March 8, 2017 | Volume: 128 | Issue: 1 | Pages: 257-263

10.1002/lary.26547 | PMID 28271539 Get It

Objectives/HypothesisChildren with bilateral true vocal fold immobility (BTVFI) may present with significant airway distress necessitating tracheostomy. The objective of this study was to review our preliminary experience with the anterior–posterior cricoid split (APCS), an endoscopic intervention used as an alternative to tracheostomy in children with BTVFI.Study DesignMulticenter review.MethodsA review of patients undergoing endoscopic APCS for BTVFI at four institutions was performed. Patients were evaluated for the ability to ventilate without the requirement for tracheostomy or reintubation. Additional data extracted included the duration of intubation following APCS, the requirement for additional procedures, and demographics. Surgical success was defined as the ability to avoid tracheostomy and to cap or decannulate without respiratory symptoms if a tracheostomy was present prior to APCS.ResultsNineteen APCS procedures were performed between October 2010 and June 2016. There were 12 male patients, the mean age at APCS was 4.7 months. BTVFI was primarily idiopathic (58%) and associated with other comorbidities (74%). All patients were candidates for tracheostomy prior to APCS. Fourteen patients (74%) were considered surgical successes. Of the unsuccessful patients, three (66%) required tracheostomy following APCS, and one was treated with a posterior cartilage graft. There was one nonsurgical mortality greater than 2 months after APCS and thought to be unrelated to the airway.ConclusionsEndoscopic APCS appears to be a safe and effective intervention for pediatric BTVFI. Under the correct circumstances, this can be performed as a single procedure, obviating tracheostomy. Further study is warranted.Level of Evidence4. Laryngoscope, 128:257–263, 2018
Mechanical circulatory support in patients with severe aortic stenosis and left ventricular dysfunction undergoing percutaneous coronary intervention
Mustafa, Ahmed, Chaker, Zakeih, Aljohani, Sami, Holmes, David R. , Alkhouli, Mohamad , Alqahtani, Fahad

Journal of Cardiac Surgery | March 8, 2017 | Volume: 32 | Issue: 4 | Pages: 245-249

10.1111/jocs.13116 | PMID 28271553 Get It

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Cynthia, X. , Northfelt, Donald W. , Forero, Andres , Anderson, Karen S. , Margenthaler, Julie A. , Aft, Rebecca , Hobday, Timothy J. , Moynihan, Timothy J. , Gillanders, William E. , Cyr, Amy, Eberlein, Timothy J. , Guo, Zhanfang , Lee, Michelle V. , Spies, Nicholas C. , Skidmore, Zachary L. , Griffith, Obi L. , Griffith, Malachi , Thomas, Shana , Bumb, Caroline, Bartlett, Cynthia Huang , Koehler, María , Al‐Kateb, Hussam , Sanati, Souzan , Hobday, Timothy, Moynihan, Timothy, Hieken, Tina, Gao, Feng , Luo, Jingqin , Goetz, Matthew P. , Hoog, Jeremy , Naughton, Michael J. , Ademuyiwa, Foluso O. , Suresh, Rama , Hieken, Tina J. , Krontiras, Helen , Vij, Kiran R , Ellis, Matthew J. , Griffith, Malachi , Griffith, Obi L

Clinical Cancer Research | March 7, 2017 | Volume: 23 | Issue: 15 | Pages: 4055-4065

10.1158/1078-0432.ccr-16-3206 | PMID 28270497 Get It

Abstract Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the antiproliferative activity of the CDK4/6 inhibitor palbociclib in primary breast cancer as a prelude to adjuvant studies. Experimental Design: Eligible patients with clinical stage II/III ER+/HER2− breast cancer received anastrozole 1 mg daily for 4 weeks (cycle 0; with goserelin if premenopausal), followed by adding palbociclib (125 mg daily on days 1–21) on cycle 1 day 1 (C1D1) for four 28-day cycles unless C1D15 Ki67 > 10%, in which case patients went off study due to inadequate response. Anastrozole was continued until surgery, which occurred 3 to 5 weeks after palbociclib exposure. Later patients received additional 10 to 12 days of palbociclib (Cycle 5) immediately before surgery. Serial biopsies at baseline, C1D1, C1D15, and surgery were analyzed for Ki67, gene expression, and mutation profiles. The primary endpoint was complete cell cycle arrest (CCCA: central Ki67 ≤ 2.7%). Results: Fifty patients enrolled. The CCCA rate was significantly higher after adding palbociclib to anastrozole (C1D15 87% vs. C1D1 26%, P < 0.001). Palbociclib enhanced cell-cycle control over anastrozole monotherapy regardless of luminal subtype (A vs. B) and PIK3CA status with activity observed across a broad range of clinicopathologic and mutation profiles. Ki67 recovery at surgery following palbociclib washout was suppressed by cycle 5 palbociclib. Resistance was associated with nonluminal subtypes and persistent E2F-target gene expression. Conclusions: Palbociclib is an active antiproliferative agent for early-stage breast cancer resistant to anastrozole; however, prolonged administration may be necessary to maintain its effect. Clin Cancer Res; 23(15); 4055–65. ©2017 AACR.
Determination of mild, moderate, and severe pain interference in patients with cancer
Shi, Qiuling , Mendoza, Tito R. , Dueck, Amylou C. , Ma, Haijun , Zhang, Jeffrey , Qian, Yi , Bhowmik, Debajyoti, Cleeland, Charles S. , Dueck, A. C. , Mendoza, Tito

Pain | March 7, 2017 | Volume: 158 | Issue: 6 | Pages: 1108-1112

10.1097/j.pain.0000000000000890 | PMID 28267060 Get It

Abstract Effective assessment and management of pain in patients with cancer is strengthened by the patient's report of how much pain interferes with daily functioning. This requires a clear delineation of different levels of pain interference. We derived optimal cutpoints for differentiating between mild, moderate, and severe pain interference assessed by the Brief Pain Inventory (BPI) and describe the prevalence and characteristics of pain-induced functional impairment in patients with cancer. Data were pooled across 3 Phase III pivotal trials. Patient-completed questionnaires included the EuroQol 5 dimensions questionnaire (EQ5D), Functional Assessment of Cancer Therapy–General Measure (FACT-G), and BPI. Optimal cutpoints for categorizing pain interference into 3 levels were derived using analysis of variance, with different cutpoint sets for BPI total interference (BPI-PITS, the average score of all 7 items), activity-related interference (BPI-WAW, the average score of work, general activity, and walking), and mood-related interference (BPI-REM, the average score of relations with others, enjoyment of life, and mood) as independent variables and EQ5D–visual analog scale and total FACT-G score as dependent variables. To validate the cutpoints, we assessed whether interference categories were in concordance with Eastern Cooperative Oncology Group performance status (ECOG-PS) levels. The optimal cutpoints were (2,5) for BPI-PITS, (2,6) for BPI-WAW, and (2,5) for BPI-REM. The mild (<2), moderate (2-5 or 2-6), and severe (>5 or >6) pain interference groups were significantly concordant with ECOG-PS levels (P < 0.0001). We empirically derived patient-reported pain interference categories in relation to clinician-rated performance status. These cutpoints may facilitate the conduct and interpretation of clinical evaluation, symptom epidemiology, and clinical trials.
Optical Coherence Tomography and Neuro-Ophthalmology
Chen, John J. , Chen, John J

Journal of Neuro-Ophthalmology | March 7, 2017 | Volume: 38 | Issue: 1 | Pages: e5-e8

10.1097/wno.0000000000000505 | PMID 28266953 Get It

Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study
Barton, Debra L. , Schroeder, Kelliann C. Fee, Banerjee, Tanima , Wolf, Sherry L., Keith, Timothy Z., Elkins, Gary R.

Menopause | March 7, 2017 | Volume: 24 | Issue: 7 | Pages: 774-782

10.1097/gme.0000000000000837 | PMID 28266949 Get It

Abstract Objective: The need for effective nonhormonal treatments for hot flash management without unwanted side effects continues. The primary aim of this pilot study was to evaluate the effect of combining a nonhormonal pharmacologic agent with a behavioral treatment for hot flash reduction. Methods: Seventy-one postmenopausal women were randomized to one of four groups: venlafaxine 75 mg + hypnosis (VH) versus venlafaxine 75 mg + sham hypnosis (VSH) versus a placebo pill + hypnosis (PH) versus placebo pill + sham hypnosis (PSH). Women recorded hot flash severity and frequency in a daily diary, in real time. The intrapatient difference in hot flash score (frequency × severity) at 8 weeks was analyzed using a General Estimating Equation model, using VSH as the referent arm, controlling for baseline hot flashes. Results: The active arms including PH or VH were not statistically significantly different than VSH (P = 0.34, P = 0.05, respectively). Women in each active arm reported hot flash reductions of about 50%, with the PSH group reporting a 25% reduction. Women receiving the PSH reported statistically significantly smaller reductions in hot flash score than women in the referent VSH arm (P = 0.001). There were no significant negative side effects during the course of the study. Conclusions: Hypnosis alone reduced hot flashes equal to venlafaxine alone, but the combination of hypnosis and venlafaxine did not reduce hot flashes more than either treatment alone. More research is needed to clarify whether combining hypnosis with a different antidepressant would provide synergistic benefits.
Giant Cell Tumor of the Metacarpal: Case Report
Lewallen, Laura, Wagner, Eric R. , Moran, Steven L. , Lewallen, Laura W, Wagner, Eric R

HAND | March 7, 2017 | Volume: 12 | Issue: 5 | Pages: NP113-NP117

10.1177/1558944717697431 | PMID 28719994 Get It

Background: Giant cell tumor (GCT) of bone is a benign, though locally aggressive tumor, classically described as an eccentric lytic lesion, often with cortical expansion and destruction. It typically involves the metaphysis or epiphysis of long bones in skeletally mature patients, with a slight female predominance. The incidence in the small bones of the hand has been reported to be 2% to 5%. Methods: Treatment options have evolved in recent years, and currently include intralesional curettage with or without adjuvant therapy, wide resection, and occasionally amputation. Results: In this report, we present a long-term follow-up (10 years) of a patient with GCT involving a metacarpal, who was initially reconstructed with a metacarpal head allograft, which was eventually revised to a metacarpophalangeal (MCP) total joint arthroplasty. Conclusions: To our knowledge, this is the only report of pyrocarbon being used for tumor reconstruction and the only report of late MCP allograft salvage.